Fact CheckerSign in

NCT06473714Recruiting

Effects of Transcranial Direct Current Stimulation (tDCS) on Inhibition and Brain Function in Primary Progressive Aphasia

Source: ClinicalTrials.gov · Last updated 5 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Primary progressive aphasia (PPA) is a focal dementia characterized by primary impairment of language abilities and functional disturbances associated with language. Although PPA is a progressive disorder, new techniques are being proposed to try to activate parts of the brain previously thought to be potentially inactive, due to the possibility of "neuroplasticity". This concept refers to our brain's modularity and learning potential. Transcranial direct current stimulation is a powerful neuromodulatory technique, in which a small current is applied to the participant's scalp through the targeted positioning of an anode and a cathode. The positive or anodal stimulation of tDCS is supposed to increase neuronal activity under the electrode, while cathodal stimulation is supposed to do the opposite. This project will provide new insights into the nature of the neural activity underlying executive functions in people with primary progressive aphasia compared to those without. The investigators expect to find reduced amplitude of electrophysiological responses and lower accuracy in people with primary progressive aphasia compared with healthy controls. Given the results of previous studies showing the efficacy of tDCS protocols in the treatment of aphasia, the investigators might expect them to improve executive functions. If so, the investigators expect significantly greater electrophysiological responses after stimulation sessions compared with sham conditions. This project is of great clinical relevance. This research will improve current therapeutic protocols used in the treatment of PPA by providing critical findings on whether and how the use of tDCS improves executive functions. Crucially, the research will advance knowledge of executive function decline as a sensitive marker of PPA, informing us about the possibility of early detection of this disorder. At the same time, the investigators will analyze the possibility of controlling symptomatological evolution via the analysis of acoustic and vocal markers. This will enable us to observe the evolution of sensory markers such as acoustic markers according to symptomatological evolution. This will enable us to check whether acoustic markers correlate with the patient's level of symptomatological impairment and/or pathological physiological data.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
20 (estimated)
First submitted
19 Jun 2024
Start date
4 Nov 2024
Primary completion date
Sept 2027
Lead sponsor
Centre Hospitalier Universitaire de Nice
NCT number
NCT06473714

What you commit to

  • Study type: Interventional
  • Planned participants: 20
  • From 4 Nov 2024 to the primary completion date, Sept 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Active use of psychotropic drugs
  • Treatment with tDCS or TMS in the last 3 months
  • Additional language therapy

Other illness

  • Presence of neurodevelopmental disorders or non-degenerative neurological disorders
  • Post-stroke aphasia
  • Language or cognitive disorders too severe to allow task performance or communication
  • Pre-existing psychiatric disorders; severe depression, schizophrenia
  • People with pacemakers or metal implants, epilepsy
  • Presence of a medical condition that represents a contraindication to tDCS

Other

  • Pregnancy or breast-feeding

Who the study is looking for

  • Be a male or female over the age of 18 with a primary progressive aphasia diagnosis
  • Available for treatment and testing sessions
  • able to read and speak French
  • Be right-handed

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHU de Nice
Coordinator of this site? Confirm its status
NiceFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.